|
| Particle used | Biological polymer | Particle size | Cells type | Particle concentration | Toxicity assay | Result | Reference |
|
| Feridex (FDA approved) | Dextran | 80–150 nm | rMSC & mMSC | 25 μg/mL | Live/dead (7 days after labelling) differentiation assays | No loss of cell viability observed after 7 days with or without either TA | [32] |
| Ferric oxide (noncommercial) | Poly-L-lysine | 15 nm | HUC | 20 μg/mL | MTT (5 days continued culture) cellular apoptosis—annexin V/PI double stainassay | | [19] |
| Noncommercial | Silica | 110 nm | hMSCs | 200 μg/mL | MTT ( 1 hr and 24 hrs) Trypan Blue | No reduction in viability after 1 hour. No reduction in cell proliferation | [38] |
| Feridex | Dextran | 80–150 nm | hMSC | 100 μg/mL | FACS ( fluorescence-activated cell sorting) to evaluate cell death—to determine if iron oxide incorporation affects surface markers expression | No reduction in viability after 12 hours | [39] |
| Iron fluorescent particle | Polystyrene | 900 nm | pMSC | | Trypan Blue MTT Morphological observations Differentiation studies | Cells maintained viability and retained label for up to 3 months. Differentiation capacity not altered | [22] |
| Manganese oxide nanoparticles | Mesoporous silica | 65 nm | mMSCs | | MTS | 75% cell viability Limited cell differentiation in the osteogenic lineage | [40] |
| Commercially available | | 1630 nm | rMSCs | 2.8 μg/mL | Trypan Blue | Did not affect cell viability | [41] |
| Feridex | Dextran | 150 nm | ESCs | 50 μg/mL | Trypan Blue | Did not affect cell viability | [42] |
| | HEDP | | rMSC | 25, 50, 100 μg/mL | MTS | Cell viability not affected at lower concentrations but viability decreased to 70% at 100 μg/mL | [43] |
| Feridex | uncoated | 80–150 | hMSC | 50–250 μg/mL |
Comet assay
| Did not affect viability | [44] |
|